Today, we were live at the Dermatomyositis' Externally-Led Patient-Focused Drug Development Meeting. Myositis Support and Understanding Association, Inc. (MSU) and The Myositis Association(TMA) partnered to bring this advocacy opportunity to all our Dermatomyositis patients. Thanks to our MSU president Lynn Wilson who lead us into this journey and Paula Eichenbrenner, MBA, CAE for making this possible as a true Patient Organization Partnership. Thanks to the FDA team for guiding us and keep us grounded on the patient voices. Also kudos to all the organization and patient volunteers(Benita Moyers, Karen Cheng, Martha Arnold,Linda J. Kobert) who managed the behinds the scenes details, listening to fellow patients and made all of this possible. It took us a year to get here, from the Letter of Intent to the FDA last May. We worked out a plan, hired HPM as consultants , started a fundraising campaign (six industry partners volunteered), and, most importantly of all, we asked for patients volunteers from every walk of life to tell their stories. The stories reflected the current status of the patient symptoms and The Adult Dermatomyositis Patient Focus Drug Development (PFDD) session is a conference organized by patients and patient organizations for patients. It serves as a unique platform for individuals living with adult dermatomyositis to come together and actively participate in the drug development process. In the session, patients share their personal experiences, insights, and priorities regarding the management and treatment of dermatomyositis. The aim was to ensure that the patient's perspective is central to decision-making processes, ultimately influencing the development of new therapies and improving the overall care and support available to those affected by DM. Finally wouldn't have been able to do this without the support of the Myositis Research Community around the world, and here in the USA to our Key Opinion Leaders that volunteer their time to present today: Dr. Lisa Christopher-Stine and Dr. Rohit Aggarwal, introducing the stories of the patients. You can see the live event here (and the future recording of it) here: www.dermatomyositis-el-pfdd.corg.
Manuel Lubinus’ Post
More Relevant Posts
-
LifeScience Executive Contributing to Lifesaving Therapies | Dad of Daughters | Ocean Advocate
👉 A New Era for Patient Recruitment and Retention in Rare Disease Norstella #pharmaceuticals #biopharma #raredisease #patientrecruitment #clinicaloperations #drugdevelopment #clinicaltrials #pharmapipeline #therapeuticarea #lifesciences
-
UK's NICE Approves Lilly's Omvoh for Ulcerative Colitis Despite FDA Rejection, Citing Cost-Effectiveness and Clinical Benefits Eli Lilly's ulcerative colitis drug, mirikizumab (Omvoh in the UK), received a favorable recommendation from England's NICE, making it the first IL-23p19 inhibitor in NHS England's arsenal. With limited treatment options for over half a million UK residents with inflammatory bowel diseases, this is a milestone. Mirikizumab succeeded in phase 3 trials and gained regulatory approval in the UK, Europe, and Japan, but faced FDA setbacks in the US. Its potential in treating Crohn's disease is a key focus for Eli Lilly, with analysts projecting substantial sales by 2028, hinting at a significant pharmaceutical impact. Interested in diving deeper into this news? For the latest updates on pharmaceutical developments, visit Pharmtales, your source for the Latest Pharma News. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #niceapproves #fda #elililly #drugs #pharmaceuticalcompanies https://lnkd.in/dVYTgw_n
NICE approves Lilly’s Omvoh for ulcerative colitis after FDA rejection, citing cost-effectiveness and clinical benefits
https://pharmtales.com
-
"Tyruko is approved as a monotherapy to treat all indications covered by reference medicine Tysabri®* (natalizumab) for relapsing forms of MS, including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS) and active secondary progressive disease, as well as Crohn’s disease in adults.1" #DahliaConsulting #BiopharmaceuticalIndustry #CommercialLifeSciences #ManagementConsultant #LifeSciencesBusinessStrategy #GlobalPharma #GlobalBioTech #SupplychainOperations #CommercialOperations #CGTcommercialization #Manufacturing #QualityAssurance #OperationalExcellence #FinancialAnalysis #OpModelDesign #LifeScience #BioTechnology #Bioprocessing #Biosimilars #BioPharmaIndustry #MedicalResearch #CDMO #GMP #GMPbatch #GMPmanufacturing #GenomeEditing #GeneTherapy #CellTherapy #Car_T #mRNA #cGMP #ClinicalGradeManufacturing #ClinicalGradeProduction #BiologicsLicenseApplication #BLA #Pharmaceuticals #RegenerativeMedicine #Sandoz #Novartis #FDAapproval #Tyruko #NatalizumabSztn #MultipleSclerosis #MS #Monotherapy #ClinicallyIsolatedSyndrome #CIS
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
sandoz.com
-
🤩 Kicking off 2024 with positive news in the world of Pharmacovigilance with the promising outcomes in a Kidney Disease Trial! 💊 The study’s findings revealed that half of the participants treated had a clinically meaningful reduction by 30% or more in albuminuria. 🌍 The results of this study will help to inform a Phase 3 clinical trial and will be evaluated in 11,000 patient participants worldwide. #pharmacovigilance #drugsafety #clinicaltrial #phase2 #research https://lnkd.in/eVVsbufN
Drug Shows Promise in Kidney Disease Trial
technologynetworks.com
-
Dry Eye Disease Clinical Trial and Pipeline Insight Report 2023 | 50+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space: Dry Eye Disease Clinical Trial (Albany, USA) DelveInsight’s ‘Dry Eye Disease Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline dry eye disease therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, and the … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech
Dry Eye Disease Clinical Trial and Pipeline Insight Report 2023 | 50+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space
https://www.abnewswire.com/pressreleases
-
Dry Eye Disease Clinical Trial and Pipeline Insight Report 2023 | 50+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space: Dry Eye Disease Clinical Trial (Albany, USA) DelveInsight’s ‘Dry Eye Disease Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline dry eye disease therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, and the … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech
Dry Eye Disease Clinical Trial and Pipeline Insight Report 2023 | 50+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space
https://www.abnewswire.com/pressreleases
-
Dry Eye Disease Clinical Trial and Pipeline Insight Report 2023 | 50+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space: Dry Eye Disease Clinical Trial (Albany, USA) DelveInsight’s ‘Dry Eye Disease Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline dry eye disease therapies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, and the … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech
Dry Eye Disease Clinical Trial and Pipeline Insight Report 2023 | 50+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space
https://www.abnewswire.com/pressreleases
-
Jardiance Receives FDA Approval for Chronic Kidney Disease, Rivaling AstraZeneca's Drug Eli Lilly and Boehringer Ingelheim have secured FDA approval for their SGLT2 inhibitor, Jardiance, to treat adult patients with chronic kidney disease (CKD). This milestone expands treatment options for the 35 million adults in the US with CKD, following European approval. Jardiance's approval is based on the EMPA-KIDNEY trial, which demonstrated a 28% risk reduction in kidney disease progression or cardiovascular death. It now competes with AstraZeneca's Farxiga in the CKD space, both achieving strong sales figures. Jardiance's versatility also extends to heart failure and diabetes treatment, cementing its impact. If you're eager to delve deeper into pharmaceutical industry developments and stay informed about the latest news, consider visiting Pharmtales, your source for the Latest Pharma News. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #fdaapproval #kidneydisease #jardiance #pharmaceuticalcompanies https://lnkd.in/daiqrmxM
Jardiance gets FDA green light for chronic kidney disease, challenging AstraZeneca’s rival drug
https://pharmtales.com
-
Ionis' Olezarsen Shows Promise in Reducing Triglycerides and Pancreatitis in Rare Disease Patients Ionis Pharmaceuticals has achieved a significant milestone in its phase 3 clinical trial for lipid-lowering therapy, olezarsen, in patients with familial chylomicronemia syndrome (FCS). The trial demonstrated a statistically significant reduction in triglyceride levels with the higher 80-mg dose, meeting its primary endpoint. Importantly, no acute pancreatitis events were reported in the 80-mg group, contrasting with 11 in the placebo group. Ionis plans to seek FDA approval in early 2023, potentially offering the first-ever FCS treatment in the United States. Success in severe hypertriglyceridemia trials could lead to significant future sales. If you're interested in continuing to read the full story and want to stay updated with the Latest Pharma News in USA, visit Pharmtales. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #fda #fdaapproval #triglycerides #pancreatitis #fcsreatment #unitedstates #ionis https://lnkd.in/djdqE-ye
Ionis’ olezarsen slashes triglycerides and pancreatitis in rare disease patients
https://pharmtales.com
-
Skyrizi Triumphs Over Stelara in Crohn’s Disease Head-to-Head Trial AbbVie's Skyrizi has proven significantly more effective than Johnson & Johnson's Stelara in treating Crohn's disease, according to detailed results from the phase 3 SEQUENCE trial. Skyrizi achieved clinical remission rates of 61% at Week 48, doubling the endoscopic remission rate to 32%. The trial results exceeded initial expectations of noninferiority. Skyrizi's rapid market capture in the US among Crohn's patients positions it as a successor to Humira in AbbVie's inflammatory disease portfolio. Its competition with Pfizer's Velsipity and the overall market landscape holds further intrigue. Interested in delving deeper into this news? For the latest updates on pharmaceutical industry developments, visit Pharmtales, your source for the Latest Pharma News. #pharma #pharmaceutical #pharmtales #latestnews #pharmanews #pharmaceuticalindustry #abbvie #jnj #johnsonandjohnson #pfizer #pharmaceuticalcompanies https://lnkd.in/d_dtCequ
AbbVie’s Skyrizi beats J&J’s Stelara in head-to-head Crohn’s disease trial
https://pharmtales.com
